|
Market Closed -
Nasdaq
07:00:00 31/10/26 am AEDT
|
5-day change | 1st Jan Change | ||
| 1.180 USD | -5.60% |
|
-5.60% | -13.87% |
Company Valuation: Allogene Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,126 | 907.1 | 540.2 | 446.6 | 307.9 | 407.7 | - | - |
| Change | - | -57.34% | -40.45% | -17.32% | -31.06% | 32.41% | - | - |
| Enterprise Value (EV) 1 | 1,317 | 330.6 | 91.47 | 234.8 | 347 | 211.2 | 257.5 | 76.58 |
| Change | - | -74.89% | -72.33% | 156.69% | 47.8% | -39.16% | 21.95% | -70.26% |
| P/E | -7.89x | -2.71x | -1.54x | -1.61x | -1.57x | -1.96x | -1.84x | -2.11x |
| PBR | 2.32x | 1.36x | 1.06x | 1.07x | 1.07x | 1.02x | 2.05x | 0.91x |
| PEG | - | -0.1x | 0.16x | 0x | 0x | 0.1x | -0.28x | 0.2x |
| Capitalization / Revenue | 55.2x | 3,733x | 5,686x | 20,300x | - | 107x | 33.7x | 4.82x |
| EV / Revenue | 34.2x | 1,361x | 963x | 10,673x | - | 55.3x | 21.3x | 0.9x |
| EV / EBITDA | -5.37x | -1.03x | -0.29x | -0.96x | -1.76x | -1.05x | -1.07x | -0.28x |
| EV / EBIT | -5.15x | -0.99x | -0.28x | -0.91x | -1.66x | -1.06x | -1.11x | -0.35x |
| EV / FCF | -6.38x | -1.46x | -0.38x | -1.17x | -2.32x | -1.67x | -1.76x | -0.61x |
| FCF Yield | -15.7% | -68.3% | -262% | -85.6% | -43.1% | -59.8% | -56.7% | -164% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.89 | -2.32 | -2.09 | -1.32 | -0.87 | -0.6022 | -0.642 | -0.5596 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 38.49 | 0.243 | 0.095 | 0.022 | - | 3.822 | 12.09 | 84.64 |
| EBITDA 1 | -245.3 | -321.2 | -313.5 | -243.8 | -197 | -200.2 | -239.7 | -271.5 |
| EBIT 1 | -255.8 | -335.4 | -327.7 | -257.5 | -209.3 | -199.1 | -232.9 | -218.3 |
| Net income 1 | -257 | -332.6 | -327.3 | -257.6 | -190.9 | -185.3 | -219.8 | -212.4 |
| Net Debt 1 | -809.5 | -576.5 | -448.7 | -211.8 | 39.16 | -196.5 | -150.2 | -331.1 |
| Reference price 2 | 14.920 | 6.290 | 3.210 | 2.130 | 1.370 | 1.180 | 1.180 | 1.180 |
| Nbr of stocks (in thousands) | 142,516 | 144,210 | 168,277 | 209,672 | 224,730 | 345,491 | - | - |
| Announcement Date | 23/2/22 | 28/2/23 | 14/3/24 | 13/3/25 | 12/3/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.96x | 55.25x | -1.05x | -.--% | 408M | |
| 16.87x | 6.34x | 12.15x | 1.77% | 63.77B | |
| 30.14x | 8.25x | 27.02x | 0.04% | 56.37B | |
| 37.48x | 6.65x | 19.85x | 0.86% | 54.62B | |
| 34.93x | 3.32x | 14.34x | -.--% | 44.06B | |
| 48.85x | 5.63x | 30.81x | -.--% | 42.11B | |
| -19.86x | 192.36x | -21.16x | -.--% | 41B | |
| 47.33x | 8.41x | 28.18x | -.--% | 34.92B | |
| 32x | 8.13x | 21.15x | 0.41% | 32.82B | |
| -64.56x | 13.05x | -73.23x | -.--% | 24.7B | |
| Average | 16.12x | 30.74x | 5.80x | 0.31% | 39.48B | |
| Weighted average by Cap. | 22.07x | 26.37x | 10.92x | 0.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ALLO Stock
- Valuation Allogene Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
